Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation.
- Author:
Jing LIU
1
;
Heng-Xiang WANG
;
Lian-Ning DUAN
;
Hong-Min YANG
;
Mei XUE
;
Ling ZHU
;
Li DING
;
Zhi-Dong WANG
Author Information
1. Department of Hematology, Air Force General Hospital, Beijing 100036, China. liujingemail@126.com
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Antibodies, Monoclonal;
therapeutic use;
Bone Marrow Transplantation;
adverse effects;
Child;
Child, Preschool;
Drug Resistance;
Female;
Graft vs Host Disease;
drug therapy;
Hormones;
pharmacology;
Humans;
Interleukin-2 Receptor alpha Subunit;
immunology;
Recombinant Fusion Proteins;
therapeutic use;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2009;17(1):160-163
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the efficacy and feasibility of anti-CD25 monoclonal antibody (basiliximab) in treating steroid-refractory acute graft-versus-host disease (aGVHD) following haploidentical bone marrow transplantation (hiBMT). 15 cases who developed II-IV grade steroid-resistant aGVHD after haploidentical BMT were treated by intravenous injection of basiliximab at a dose of 20 mg on days 1 and 4. In those patients not achieving CR after 1 week, basiliximab injection was repeated. The results showed that 8 cases (53.33%) got complete response (CR). Out of them 4 cases have been still in disease-free survival, 2 cases have been in survival with limited cGVHD, 2 cases died from pulmonary infection; 3 cases (65%) got partial response (PR), out of whom 1 case has been still in disease-free survival, one died from GVHD and infection, and another one died from pulmonary infection; 4 cases without response died from GVHD, pulmonary infection and cardiac failure. Overall response rate was 73.3% and long-term survival rate was 46. 7%. There were no infusion-associated side-effects after treatment with basiliximab. It is concluded that the anti-CD25 monoclonal antibody is efficacious and feasible for steroid-refractory grade II-IV aGVHD after hiBMT, but the overall survival rate is low. Infection is the main cause of death. Thereby, it is especially important to strengthen environmental protection and prevent infection.
